Syndex Bio unveils mcPCR technology at AGBT 2026 following $15.5 M seed financing
Syndex Bio unveils mcPCR technology at AGBT 2026 following $15.5 M seed financing is drawing significant interest across the industry.
Syndex Bio, a biotechnology company advancing next?generation molecular diagnostics, today announced the introduction of its proprietary mcPCR™ (methyl?copying PCR) platform at the Advances in Genome Biology and Technology (AGBT) conference in Orlando, Florida.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Clean Max Enviro Energy vs Shree Ram Twistex IPO: Where to invest? Check GMP
- Trump says US received over 80 million barrels of Venezuelan Oil, but shipments likely lower
- The right way to eat mangoes and other fruits: Expert's tips
- CrossCountry Consulting Acquires CNM, Expanding West Coast Presence
Source: Original →